Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 06, 2023, titled "(1) Zydus receives final approval from the USFDA for Acetazolamide Tablets USP, 125 mg and 250 mg and (2) Zydus receives final approval from the USFDA for Carbidopa and Levodopa Tablets USP, 10 mg/100 mg, 25 mg/100 mg, and 25 mg/250 mg ".